Cortisol Levels and Mortality in Septic Shock ICU Patients

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAnkara Etlik City Hospital

About this trial

This prospective observational study aims to evaluate the prognostic value of cortisol levels and their dynamic changes in critically ill patients with sepsis and septic shock admitted to the intensive care unit. Cortisol plays a crucial role in maintaining hemodynamic stability and modulating the inflammatory response during critical illness, and relative adrenal insufficiency has been associated with worse clinical outcomes.

Adult patients admitted to the intensive care unit with sepsis or septic shock will be enrolled and followed prospectively. Serum cortisol levels will be measured, and their association with clinical outcomes, including intensive care unit mortality, 28-day mortality, and 90-day mortality, will be analyzed. In addition, the relationship between cortisol levels and disease severity scores such as SOFA and APACHE, as well as laboratory parameters including inflammatory biomarkers, will be evaluated.

The findings of this study are expected to contribute to the early identification of high-risk patients and improve prognostic assessment in critically ill patients with sepsis and septic shock.

Eligibility criteria

Qualifiers

Age 18 years or older

Admission to the intensive care unit for more than 24 hours

Presence of a clinically or microbiologically confirmed source of infection

Diagnosis of sepsis or septic shock during ICU stay

Disqualifiers

Pregnancy

Known disorders of the hypothalamic-pituitary-adrenal (HPA) axis

Known disorders affecting cortisol secretion 4.Long-term systemic glucocorticoid use (≥3 months)

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

No trial groups listed

Sponsors and collaborators